If the D1(A12) was unable to inhibit TNF-α shedding by ADAM17 deep in the tumour this pharmacokinetic feature could also explain the discrepancy between the in vitro and in vivo studies, as the cells in vitro would all be exposed to the antibody. The gene discussed is TNF; the disease is neoplasm.